Skip to main content
Immuron Ltd logo

Immuron Ltd — Investor Relations & Filings

Ticker · IMRN ISIN · US45254U1016 LEI · 529900ZIDI5C9C9TTI91 ASX Manufacturing
Open in API
Filings indexed 1,605 across all filing types
Latest filing 2026-06-03 Regulatory Filings
Country AU Australia
Listing ASX IMRN

About Immuron Ltd

https://www.immuron.com.au

Immuron Ltd. is a clinical and commercial-stage biopharmaceutical company focused on developing and commercializing a novel class of orally delivered, specifically targeted polyclonal antibodies. The company's proprietary technology platform is based on polyclonal immunoglobulins (IgG) derived from hyper-immune bovine colostrum to address unmet medical needs, primarily related to gastrointestinal and enteric diseases. Its commercialized products include Travelan®, for reducing the risk of travelers' diarrhea, Protectyn®, for supporting gut and liver function, and ProIBS®, for relieving symptoms of Irritable Bowel Syndrome. Immuron's clinical pipeline includes therapeutic candidates for infectious diseases such as Clostridioides Difficile and Vancomycin-Resistant Enterococci.

Recent filings

Filing Released Lang Actions
Change in substantial holding 5 pages 321.9KB
Regulatory Filings
2026-06-03 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2026-05-28 English
Response to ASX Price Query 3 pages 231.0KB
Regulatory Filings Classification · 88% confidence The document is correspondence between Immuron Limited and the ASX in response to an ASX ‘price query’ under Listing Rule 18.7. It contains the company’s formal answers to ASX questions about recent trading movements and confirms compliance with continuous disclosure rules. It does not present financial data, nor is it an investor presentation or reporting of results; it is a regulatory compliance letter and falls under the general regulatory filings category.
2026-05-27 English
Emerging Growth Conference 15 pages 2.9MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by the CEO of Immuron Limited at the Emerging Growth Conference, dated May 8, 2026. It includes extensive information about the company's technology platform, products, pipeline, market, and forward-looking statements. The text explicitly mentions it is an "Investor Presentation" and contains slides and detailed descriptions typical of investor presentations. There are no financial statements or quarterly/annual report data, nor is it a brief announcement or regulatory filing. The length and content align with a presentation aimed at investors about company strategy, products, and outlook, not a formal report or regulatory filing. Therefore, the document fits the category of Investor Presentation (IP).
2026-05-07 English
Emerging Growth Conference 3 pages 437.9KB
Investor Presentation Classification · 90% confidence The document is a press release announcing that the CEO of Immuron Limited will present at the Emerging Growth Conference. It includes background information about the company, its products, and references to scientific studies. There are no financial statements, no detailed financial performance data, no regulatory filings, no voting results, no management or board changes, no earnings data, and no legal proceedings. The document is essentially an investor relations announcement about an upcoming presentation event. It does not contain a transcript of the presentation, nor is it a report or detailed investor presentation document. Given the nature of the content, this fits best as an Investor Presentation (IP) type document, as it is focused on informing investors about the CEO's participation in a conference and provides company and product information relevant to investors. Confidence is high because the document is clearly an announcement of a presentation event with detailed company and product information, typical of investor presentations.
2026-04-29 English
Immuron Double Digit 3Q Sales Growth 3 pages 439.6KB
Earnings Release Classification · 98% confidence The document is an ASX/NASDAQ announcement summarizing Q3 sales results (unaudited) and year-to-date figures, providing highlights and forward-looking statements typical of an earnings press release. There are no full financial statements or management discussion of detailed line items as in an interim report. This aligns with the definition of an Earnings Release (ER). 9M 2026
2026-04-16 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.